Cytisine versus varenicline for smoking cessation in New Zealand indigenous Maori: a randomized controlled trial.

ABSTRACT:

Aim

To determine whether cytisine was at least as effective as varenicline in supporting smoking abstinence for ≥ 6 months in New Zealand indigenous Māori or whānau (extended-family) of Māori, given the high smoking prevalence in this population.

Design

Pragmatic, open-label, randomized, community-based non-inferiority trial.

Setting

Bay of Plenty, Tokoroa and Lakes District Health Board regions of New Zealand.

Participants

Adult daily smokers who identified as Māori or whānau of Māori, were motivated to quit in the next 2 weeks, were aged ≥ 18 years and were eligible for subsidized varenicline. Recruitment used multi-media advertising.

Interventions

A total of 679 people were randomly assigned (1 : 1) to receive a prescription for 12 weeks of cytisine o

SUBMITTER: Walker N 

PROVIDER: S-EPMC8519028 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature